Post Office to offload two Glasgow branches
The last two remaining directly-owned branches of the Post Office in Glasgow are to be offloaded to franchisees by the autumn.
The Post Office announced today (Tuesday, April 8) that following a board decision, it is moving to a fully franchised network.
The branches at 136 West Nile Street in the city centre and 230 Springburn Way in Springburn are among the last 108 in the UK directly owned and run by the company to be franchised.
The Post Office stressed that those communities that currently have a directly-managed branch will continue to be able to access their services either at, or near to, the same location.
It also said that it will work with franchise partners with a clear track record of successfully running Post Office services or similar customer-focused retail to ensure communities in these 108 locations will "continue to receive a high quality of service once their directly-managed branch is franchised.'
The news follows the Post Office's announcement last November of its five-year Transformation Plan to deliver a 'New Deal for Postmasters'.
The Post Office said the plan, which is subject to government funding, will increase postmaster renumeration by an additional £250 million a year by 2030.
Nigel Railton, Post Office chair, said: 'Moving to a fully franchised network is one part of enabling the Post Office to deliver a 'New Deal for Postmasters', helping to create a long-term, sustainable future for the Post Office.
'By franchising these branches, we are protecting access to our services for communities right across the UK and realising £40 million worth of savings that will enable us to uplift postmasters' remuneration by up to 10%.
'Over the coming months, we will continue to work with our unions to ensure that we treat our staff working in these 108 branches with care and respect through this transition, consulting with them on proposed changes.
'The 108 Post Offices will either stay in the same location where possible or be located close to the existing location, meaning customers will continue to have access to a full suite of products and services.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 hours ago
- Yahoo
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, June 06, 2025--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 39,345 shares of the Company's common stock to four new employees (the "Inducement Grants") on June 5, 2025 (the "Grant Date"). The Inducement Grants have been granted pursuant to the Company's 2025 Inducement Plan (the "Plan"). The Inducement Grants were granted as an inducement material to these individuals entering into employment with Neurogene in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Grants have an exercise price per share that is equal to the closing price of Neurogene's common stock on the Grant Date. The Inducement Grants will vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date and thereafter in equal portions upon the lapse of each three-month period over the following 36-month period, subject to the employee's continued employment with Neurogene through the applicable vesting dates. About Neurogene The mission of Neurogene is to treat devastating neurological diseases to improve the lives of patients and families impacted by these rare diseases. Neurogene is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders. This includes selecting a delivery approach to maximize distribution to target tissues and designing products to maximize potency and purity for an optimized efficacy and safety profile. The Company's novel and proprietary EXACT™ transgene regulation platform technology allows for the delivery of therapeutic levels while limiting transgene toxicity associated with conventional gene therapy. Neurogene has constructed a state-of-the-art gene therapy manufacturing facility in Houston, Texas. CGMP production of NGN-401 was conducted in this facility and will support pivotal clinical development activities. For more information, visit View source version on Contacts Company Contact: Cara MayfieldVice President, Corporate Investor Contact: Melissa ForstArgot PartnersNeurogene@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
14 hours ago
- Yahoo
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, June 06, 2025--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 39,345 shares of the Company's common stock to four new employees (the "Inducement Grants") on June 5, 2025 (the "Grant Date"). The Inducement Grants have been granted pursuant to the Company's 2025 Inducement Plan (the "Plan"). The Inducement Grants were granted as an inducement material to these individuals entering into employment with Neurogene in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Grants have an exercise price per share that is equal to the closing price of Neurogene's common stock on the Grant Date. The Inducement Grants will vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date and thereafter in equal portions upon the lapse of each three-month period over the following 36-month period, subject to the employee's continued employment with Neurogene through the applicable vesting dates. About Neurogene The mission of Neurogene is to treat devastating neurological diseases to improve the lives of patients and families impacted by these rare diseases. Neurogene is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders. This includes selecting a delivery approach to maximize distribution to target tissues and designing products to maximize potency and purity for an optimized efficacy and safety profile. The Company's novel and proprietary EXACT™ transgene regulation platform technology allows for the delivery of therapeutic levels while limiting transgene toxicity associated with conventional gene therapy. Neurogene has constructed a state-of-the-art gene therapy manufacturing facility in Houston, Texas. CGMP production of NGN-401 was conducted in this facility and will support pivotal clinical development activities. For more information, visit View source version on Contacts Company Contact: Cara MayfieldVice President, Corporate Investor Contact: Melissa ForstArgot PartnersNeurogene@
Yahoo
19 hours ago
- Yahoo
Post Office compensation chief let go after criticism by Sir Alan Bates
The Post Office director responsible for compensating victims of the Horizon scandal has been let go amid criticism of the process by Sir Alan Bates, The Telegraph can disclose. Simon Recaldin, who headed up the Post Office's Remediation Unit, is understood to have taken voluntary redundancy and left the organisation earlier this week. His departure comes ahead of the expected publication of the first part of a public inquiry report into the scandal, which will examine the compensation process and the impact on victims. Sir Alan, whose efforts to uncover the truth about Horizon, featured in an acclaimed ITV drama, criticised the overall compensation process last month and accused the Government of presiding over a 'quasi kangaroo court'. On Friday, a Post Office spokesman said Mr Recaldin's departure was a result of a review of its operating model and a subsequent 'Post Office-wide organisational design exercise'. The Telegraph understands that Joanne Hanley, who worked at Lloyds Banking Group for more than 20 years, is now covering a large part of Mr Recaldin's previous work. Before leaving for the Post Office, Ms Hanley was a managing director and global head of client servicing, data and operations for Lloyds' corporate markets. More than 900 sub-postmasters were wrongfully prosecuted between 1999 and 2015, when Fujitsu's faulty Horizon software incorrectly suggested that they were stealing money. A public inquiry into the scandal finished hearing evidence in December 2024 and the first part of the report is expected to be published in the coming weeks. Sir Alan has been highly critical of the various compensation schemes, which he described as 'quasi-kangaroo courts' in The Sunday Times last month. Speaking to The Telegraph on Friday, Sir Alan said: 'It's not so much as throwing out the people working on the scheme, it's more about throwing out the schemes – that would be my preference. 'We have got serious concerns about the transparency and the parity across the schemes.' Sir Alan, who won a High Court battle against the Post Office in 2019, said his latest compensation offer was on a 'take it or leave it' basis and amounted to less than half of his original claim. The campaigner and more than 500 other sub-postmasters who joined him in a court action have to apply for compensation through the Group Litigation Order scheme, now administered by the Government. Separately, the Post Office runs the Horizon Shortfall Scheme, set up for victims who were neither involved in the compensation scheme nor convicted as a result of false shortfalls. Mr Recaldin, who attended the inquiry for the second time in November last year to give evidence in its final phase, apologised when it emerged that staff involved in Horizon prosecutions were given jobs managing compensation claims. A former NatWest and Royal Bank of Scotland manager, he took on the position as head of the then-Historical Matters Business Unit in January 2022. When asked about former Post Office investigators, he told the inquiry: 'So my regret – and it is a genuine regret – is that when I came in, in January 2022, that I didn't do that conflicts check, check back on my inherited team, and challenge that. 'And that I absolutely apologise for, because I think that's something that should have been done.' A Post Office spokesman said: 'As part of the Post Office's commitment to deliver a 'new deal for postmasters', we have undertaken a review of our operating model to ensure we have the right structure in place. 'We have been in consultation with a number of colleagues from across the business, including the Remediation Unit. As a result of this Post Office-wide organisational design exercise, Simon Recaldin has left the business.' Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
